文献速递眼底病与葡萄膜炎神经眼科小儿眼科与斜弱视

USH1C相关Usher综合征的临床发现与分子遗传学

Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

这项回顾性病例系列纳入28例分子确诊的USH1C相关视网膜病变患者,随访至2024年2月。研究发现该病变表现为数十年内视力缓慢下降和轻度椭圆体带丢失,抑郁与失业也有出现;携带特定错义变异者表现为避开上方的视网膜色素变性。

要点

  • USH1C相关视网膜病变以夜盲和周边视野困难为主要首发症状,视力在数十年内缓慢下降。
  • 随访5年以上的患者最佳矫正视力从基线0.30 logMAR降至0.59 logMAR。
  • 患者中报告抑郁者5/13(38.5%),失业者7/23(30.4%)。

核心结论

  • 作者认为,USH1C相关视网膜病变以数十年内视力缓慢下降和轻度椭圆体带丢失为特征,并观察到抑郁与失业,对预后和咨询有参考意义;其早发和缓慢进展提示可作为新兴疗法的潜在靶点。

研究设计与样本

  • 这是一项回顾性病例系列,纳入1989年1月至2024年2月在一家三级转诊中心评估的、经分子确诊为USH1C相关视网膜病变的患者,共28例,平均(SD)年龄27.0(12.2)岁,范围7至58岁,女性15例(53.6%)。
  • 暴露为USH1C分子确诊的致病变异;主要结局包括Snellen视力表测定的最佳矫正视力、视网膜影像特征、遗传变异和患者报告的社会结局。

主要发现

  • 共发现2个新的USH1C致病变异,18例为纯合子;首发症状包括夜盲(24/26例,92.3%)和周边视野困难(23/28例,82.1%)。
  • 较好眼(n=25)基线最佳矫正视力为0.22 logMAR(20/32);随访5年以上的15例中,基线为0.30 logMAR(20/40),降至0.59 logMAR(20/80)。
  • 在ETDRS等效值(n=15)中,平均每年下降0.53个字母(中位数0,范围0至2);24例中4例(16.7%)符合世界卫生组织重度视力损害标准(较好眼20/200或更差)。
  • 抑郁由全科医生依据患者健康问卷9记录,13例中5例(38.5%)报告抑郁;失业为末次随访时自我报告,23例中7例(30.4%)。
  • 光学相干断层扫描显示基线时21例中5例存在黄斑囊样水肿,随访时2例持续存在;平均(SD)中心子区域厚度基线为260.6(53.6)µm(n=18),随访为259.4(44.5)µm(n=15);携带错义变异c.308G>A(p.Arg103His)和c.440A>G(p.His147Arg)的患者表现为避开上方的视网膜色素变性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Expanding insight into the phenotypic spectrum, social burden of dual sensory impairment, and progression of USH1C-associated retinopathy is essential to inform prognosis and guide emerging therapies. OBJECTIVE: To characterize some genetic variants, clinical features, natural history, and social outcomes of USH1C-associated retinopathy in a patient cohort. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective case series including patients with molecularly confirmed UCH1C-associated retinopathy evaluated at a tertiary referral center from January 1989 to February 2024. EXPOSURE: Molecularly confirmed pathogenic variants in USH1C. MAIN OUTCOMES AND MEASURES: Main outcomes included best-corrected visual acuity (BCVA) measured with the Snellen chart, retinal imaging features, genetic variants, and patient-reported social outcomes. Depression was documented by general practitioners using the Patient Health Questionnaire 9. Unemployment was self-reported at last follow-up. Retinitis pigmentosa diagnosis (RP) was diagnosed based on characteristic retinal findings and visual field loss. RESULTS: A total of 28 patients (mean [SD] age, 27.0 [12.2] years; range, 7-58 years; 15 female [53.6%]) were included in this analysis. Two novel pathogenic USH1C variants were identified; 18 patients were homozygous. Presenting symptoms included nyctalopia (24 of 26 patients [92.3%]) and peripheral vision difficulties (23 of 28 patients [82.1%]). Baseline BCVA (Snellen chart) in the better-seeing eye (n = 25) was 0.22 logMAR (20/32). Among 15 patients with follow-up of 5 years or more, baseline BCVA was 0.30 logMAR (20/40), declining to 0.59 logMAR (20/80). In Early Treatment Diabetic Retinopathy Study (ETDRS) equivalents (n = 15), decline averaged 0.53 letters per year (median, 0; range, 0-2). Four of 24 patients (16.7%) met World Health Organization criteria for severe sight impairment (20/200 or worse in the better-seeing eye). Depression was reported by 5 of 13 patients (38.5%) and unemployment by 7 of 23 patients (30.4%). Optical coherence tomography revealed cystoid macular edema in 5 of 21 patients at baseline, persisting in 2 patients at follow-up. Mean (SD) central subfield thickness was 260.6 (53.6) µm at baseline (n = 18) and 259.4 (44.5) µm at follow-up (n = 15). Patients with missense variants c.308G>A (p.Arg103His) and c.440A>G (p.His147Arg) showed retinitis pigmentosa sparing the superior retina. CONCLUSIONS AND RELEVANCE: Results of this case series study suggest that USH1C-associated retinopathy was characterized by slow decline of visual acuity and modest ellipsoid zone loss over decades. Depression and unemployment were also observed, with implications for prognosis and counseling. Early onset and slow progression highlight its potential as a target for emerging therapies.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Aychoua N, de Guimarães TAC, Ponnekanti MB, et al. Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome. JAMA Ophthalmol. 2026. PMID: 41296346. doi:10.1001/jamaophthalmol.2025.4813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。